Category: clinical study retractions

Author objects to retraction after he says journal ignored his queries for three years

In 2014, a journal contacted researcher Denis Rousseau about one of his papers that had just been published online ahead of print, raising some concerns. According to Rousseau, he sent the journal a corrected figure “almost immediately,” which he believed addressed the issue.

Rousseau, a cell biologist at the University Joseph Fourier in Grenoble, France, said he then contacted the journal many times over the next three years to ask about the status of the paper — which never ended up in print — but heard nothing back.

Three years passed.

In March, the publisher finally contacted Rousseau, this time to ask him to issue a formal retraction for the paper. And despite his objections, Molecular and Cellular Biology published a sparse retraction notice, which provides little information about what went wrong:

Continue reading Author objects to retraction after he says journal ignored his queries for three years

University suggests journal correct diabetes paper. Publisher retracts it.

After a publisher learned there may be issues with a 2008 diabetes paper, it asked the author’s university to investigate. The university found evidence of image duplication, and asked the journal to consider correcting the paper.

Instead, the journal has retracted it.

The backstory involves diabetes researcher Kathrin Maedler, who has one previous retraction, as well as multiple corrections. Even the paper in question, published in Diabetes, received an erratum in 2014 regarding a duplicated image, as well as an expression of concern last August after the American Diabetes Association questioned “the reliability of the data” in both the article and erratum.

According to the expression of concern, the ADA asked the University of Bremen to investigate the issues in the paper. In October, the University of Bremen concluded that several duplications present in her work were the result of negligence, not misconduct.

To resolve the issues, the university’s rector recommended that the authors publish a second erratum with corrected figures. But after conducting its own review, the ADA overruled the university, opting instead to retract the paper:

Continue reading University suggests journal correct diabetes paper. Publisher retracts it.

Former rising star found guilty of misconduct issues 2nd retraction

A once-lauded researcher in the field of infectious disease — who has since been found guilty of misconduct — has retracted a second paper.

Last year, the University of Dundee in Scotland investigated and ultimately concluded that Robert Ryan — whose work focused on infections that can be deadly in people with lung diseases such as cystic fibrosis — had committed “serious research misconduct,” affecting multiple publications. After appealing the decision, Ryan resigned.

We covered his first retraction earlier this month, which cited multiple instances of image duplication. Now Ryan has retracted his second paper, published in 2011 in Journal of Bacteriology, also due to image problems.

Here’s the retraction notice: Continue reading Former rising star found guilty of misconduct issues 2nd retraction

Harvard teaching hospital to pay $10 million to settle research misconduct allegations

Piero Anversa

Brigham and Women’s Hospital and its parent healthcare network have agreed to pay $10 million to the U.S. government to resolve allegations it fraudulently obtained federal funding.

The case, which involves three former Harvard stem cell researchers, dates back several years. In 2014, Circulation retracted a paper by Piero Anversa, Annarosa Leri, and Jan Kajstura, among others, amidst a university investigation into misconduct allegations. Anversa and Leri — whose lab was described as filled with “fear” by one former research fellow — later sued the hospital for notifying journals of that investigation. They lost.

In the agreement announced today by the Department of Justice (DOJ), Partners Healthcare and Brigham and Women’s Hospital have agreed to pay the government $10 million to settle allegations that the researchers fraudulently obtained funding from the National Institutes of Health:

Continue reading Harvard teaching hospital to pay $10 million to settle research misconduct allegations

A shadow was cast on a bone researcher’s work. What are journals doing about his papers?

Last year, a researcher cast doubt on a bone scientist’s clinical trials, suggesting some of the findings may not be legitimate. So what’s happened since?

Since 2015, journals have retracted 14 papers by bone researcher Yoshihiro Sato, based at Mitate Hospital in Japan, for issues ranging from self-plagiarism, to problems with data, to including co-authors without their consent. (We covered the latest two retractions this week.) Last year’s analysis identified patterns in more than 30 of Sato’s clinical trials that suggest systematic problems with the results. (Sato has defended his research.)

With doubts cast on Sato’s body of work, we contacted the journals that have published his papers involving human trials, to see if any taken another look at Sato’s work; several responded. While most believe there is little reason to take further action at this time, some told us they are investigating.
Continue reading A shadow was cast on a bone researcher’s work. What are journals doing about his papers?

Harvard diabetes researcher retracts third paper

A prominent diabetes researcher based at Harvard Medical School has retracted a third paper, citing manipulation of multiple figures.

Late last year, Carl Ronald Kahn—also chief academic officer at Joslin Diabetes Center—retracted two papers for similar reasons. In November, Kahn pulled a 2005 paper from The Journal of Clinical Investigation (JCI) and a month later, he retracted a 2003 paper from The Journal of Biological Chemistry (JBC), both times citing duplications that the authors said were introduced while assembling the figures.

Last month, Kahn retracted his third paper, also published in JBC in 2003, because the authors omitted data when constructing the images. Still, the authors remain confident in their findings, given that data from other labs “have confirmed and extended the conclusions of the manuscript.”

Here’s the retraction notice: Continue reading Harvard diabetes researcher retracts third paper

“Think of the unthinkable:” JAMA retraction prompts author to urge others to share data

A few months ago, a researcher told Evelien Oostdijk there might be a problem with a 2014 JAMA study she had co-authored.

The study had compared two methods of preventing infection in the intensive care unit (ICU). But a separate analysis had produced different results.

Oostdijk, from the University Medical Center Utrecht in The Netherlands, immediately got to work to try to figure out what was going on. And she soon discovered the problem: The coding for the two interventions had been reversed at one of the 16 ICUs. This switch had “a major impact on the study outcome,” last author Marc Bonten, also from the University Medical Center Utrecht, wrote in a blog post about the experience yesterday, because it occurred at “one of the largest participating ICUs.”

When Oostdijk and a researcher not involved in the study analyzed the data again, they discovered a notable difference between the revised and original findings: The new analysis revealed that one of the interventions had a small but significant survival benefit over the other.

Oostdijk and Bonten, who supervised the re-analysis, notified their colleagues of the revised study outcomes and contacted the journal requesting a retraction and replacement, which was published yesterday in JAMA.

According to the notice of retraction and replacement:

Continue reading “Think of the unthinkable:” JAMA retraction prompts author to urge others to share data

Fraud by bone researcher takes down two meta-analyses, a clinical trial, and review

The troubles continue for a bone researcher, who’s lost multiple papers in recent months due to problems ranging from data issues to including authors without their consent.

Now, journals have retracted two more papers by Yoshihiro Sato. And in a sign of the downstream effects that fraud can have, another journal has retracted two meta-analyses by other authors that cited his work.

Earlier this month, the journal Current Medical Research and Opinion retracted the two meta-analyses because they were based on recently retracted papers by Sato, affiliated with Mitate Hospital. The two new retractions of Sato’s papers are a review and a randomized controlled trial.

Sato was not an author on the meta-analyses published in 2008 and 2011; he was, however, first and lead author on all the retracted papers referenced in the notices. The notices state that the trio of authors on the meta-analyses:

Continue reading Fraud by bone researcher takes down two meta-analyses, a clinical trial, and review

Three figures in blood pressure paper were manipulated, says journal

A pharmacology journal has retracted a 2011 paper after concluding images in three figures had been manipulated.

According to the British Journal of Pharmacology, four of the five authors claim they played no role in the manipulation. There is no comment from the remaining author, first author Ian Morecroft, a research associate at the University of Glasgow.

Here’s more from the notice, which says an investigation at the University of Glasgow is ongoing:

Continue reading Three figures in blood pressure paper were manipulated, says journal

A diabetes researcher sued his former employer for defamation. Here’s the story.

Franck Mauvais-Jarvis

The last decade hasn’t exactly been drama-free for Franck Mauvais-Jarvis, head of the Diabetes Research Program at Tulane University.

After being accused of falsifying three figures in a submitted manuscript, Mauvais-Jarvis sued his accusers and officials at his former employer — Northwestern University — for defamation and conspiracy in 2011.

In 2014, a judge dismissed the suit. We wish we could tell you more details about it—such as what the university’s misconduct investigation found, or how the lawsuit was concluded—but they remain shrouded in mystery. What we know is based on court records from the lawsuit, which we recently obtained through an unrelated public records request. Even without all the details, it’s a long, sordid tale, involving a lot of finger-pointing and allegations of misconduct.

In 2008, a former research technician in the lab of Mauvais-Jarvis, then an associate professor of medicine at Northwestern University, raised concerns of fabrication in two figures in a paper on the regulation of insulin synthesis that had been submitted the Journal of Biological Chemistry. An inquiry committee at the university unanimously concluded that research misconduct charges against Mauvais-Jarvis were not credible.

But then a third figure in the manuscript was found to be “inaccurate,” and the university initiated a second inquiry. That’s when Mauvais-Jarvis — whose papers have been cited more than 2,000 times, according to Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters — initiated a lawsuit. Continue reading A diabetes researcher sued his former employer for defamation. Here’s the story.